Non-Alcoholic Steato-Hepatitis (NASH) Drug Treatment Study
The purpose of this study is to test whether a drug called emricasan (IDN-6556) can decrease the amount of scarring (fibrosis) in the liver caused by the presence of fat. This drug will be compared with placebo in patients with NASH. Nationwide and in Europe, 330 patients will be enrolled in this study. Rush University Medical Center expects to enroll 5 patients. The treatment will be assigned randomly.
In order to participate you must meet the following criteria:
- Have NASH diagnosed via a liver biopsy.
- Have fibrosis stage 1, 2 or 3.
You will be excluded from the study if any of the following criteria apply to you:
- Have cirrhosis.
- Have severe renal impairment.
- Have uncontrolled diabetes (or a HbA1c greater than or equal to 9%).
This is a partial list of inclusion and exclusion criteria.